SeaStar Medical(NASDAQ) ICUCW

SeaStar Medical Holding Corporation is a medical device company based in Denver, Colorado, focused on developing innovative therapies to combat hyperinflammation and cytokine storms in critically ill patients. The company specializes in extracorporeal treatments targeting immune effector cells that drive systemic inflammation, leading to tissue damage and dysregulated immune responses.

Products and Services

• Extracorporeal therapies for acute kidney injury in pediatric and adult patients
• Innovative solutions for cardiorenal syndrome in congestive heart failure cases
• Targeted treatments for myocardial stunning and hepatorenal syndrome

Growth Outlook

• Expansion into diverse therapeutic domains enhances market potential
• Increasing demand for innovative treatments in critical care settings
• Strong focus on research and development to drive future product offerings

Financial Highlights

• Recent quarterly revenue of 495,000, up from 420,000 in the previous quarter
• Cash and cash equivalents of 9,348,000, providing operational stability
• Current ratio of 2.73 indicates strong liquidity position

SeaStar Medical is positioned in a growing biotechnology sector, addressing critical healthcare needs with its specialized therapies. The company's focus on research and development aims to enhance its product pipeline, potentially leading to significant advancements in treatment options for critically ill patients. Recent financial data reflects a positive trend in revenue growth, alongside a solid liquidity position, which may support ongoing operational needs and future expansion efforts. The innovative nature of SeaStar Medical's offerings aligns with increasing market demand for effective treatments in critical care, making it a noteworthy entity in the healthcare landscape.